ELCC 2023

ELCC 2023

Taletrectinib Has “Meaningful Clinical Efficacy” in ROS1+ NSCLC

By

Laura M. Healy

Publish Date April 7, 2023

Taletrectinib can produce durable responses in patients with ROS1-positive non-small cell lung cancer, a phase 2 trial suggests.

ELCC 2023

Tusamitamab Ravtansine-Based Combinations Show Activity in NSCLC

By

Laura M. Healy

Publish Date April 6, 2023

Combination regimens including tusamitamab ravtansine have demonstrated activity in a phase 2 study of patients with CEACAM5+ non-small cell lung cancer.

ELCC 2023

Upfront Osimertinib Reduces Risk of Brain Progression in EGFR-Mutant NSCLC

By

Laura M. Healy

Publish Date April 4, 2023

Upfront osimertinib can reduce the risk of brain progression, when compared with gefitinib followed by osimertinib, in advanced EGFR-mutant NSCLC, a study suggests.

ELCC 2023

Amivantamab Provides Long-Term Benefit in Heavily Pretreated NSCLC

By

Laura M. Healy

Publish Date April 4, 2023

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.